Modeling relaxed policies for discontinuation of methicillin-resistant contact precautions.

OBJECTIVE

To evaluate the economic costs of reducing the University of Virginia Hospital's present "3-negative" policy, which continues methicillin-resistant (MRSA) contact precautions until patients receive 3 consecutive negative test results, to either 2 or 1 negative.

DESIGN

Cost-effective analysis.

SETTINGS

The University of Virginia Hospital.

PATIENTS

The study included data from 41,216 patients from 2015 to 2019.

METHODS

We developed a model for MRSA transmission in the University of Virginia Hospital, accounting for both environmental contamination and interactions between patients and providers, which were derived from electronic health record (EHR) data. The model was fit to MRSA incidence over the study period under the current 3-negative clearance policy. A counterfactual simulation was used to estimate outcomes and costs for 2- and 1-negative policies compared with the current 3-negative policy.

RESULTS

Our findings suggest that 2-negative and 1-negative policies would have led to 6 (95% CI, -30 to 44; < .001) and 17 (95% CI, -23 to 59; -10.1% to 25.8%; < .001) more MRSA cases, respectively, at the hospital over the study period. Overall, the 1-negative policy has statistically significantly lower costs ($628,452; 95% CI, $513,592-$752,148) annually ( < .001) in US dollars, inflation-adjusted for 2023) than the 2-negative policy ($687,946; 95% CI, $562,522-$812,662) and 3-negative ($702,823; 95% CI, $577,277-$846,605).

CONCLUSIONS

A single negative MRSA nares PCR test may provide sufficient evidence to discontinue MRSA contact precautions, and it may be the most cost-effective option.